Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Abbisko Therapeutics2256 · HKEX | 3 assets: 2 Ph 2, 1 Ph 1 | LavengratinibPhase 2 · Non-Small Cell Lung Cancer | Mar 2027ABSK112 · Phase 1 | — | $286MDec 2025 | — | $71M |
Actinogen Medical (ASX: ACW)ACW · ASX | 1 asset: 1 Ph 3 | EmestedastatPhase 2/3 · Alzheimer's DiseasePartial signal | None on record | — | — | Ended Aug 2025Jun 2025 | ~$6.0M |
Active Biotech ABACTI · Nasdaq Stockholm | 1 asset: 1 Ph 2 | Naptumomab estafenatoxPhase 2 · Non-Small Cell Lung CancerWeak signal | 1 Mar 2027Naptumomab estafenatox · Phase 1 | — | — | — | — |
AdAlta1AD · ASX | 1 asset: 1 Ph 1 | AD-214Phase 1 · Chronic Kidney DiseaseWeak signal | None on record | — | $0.9MJun 2025 | Ended Jul 2025 | — |
AdociaADOC · Euronext Paris | 1 asset: 1 Ph 3 | THDB0206Phase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
Agomab Therapeutics NVAGMB · Nasdaq | 1 asset: 1 Ph 2 | ontunisertibPhase 2 · Fibrostenosing Crohn's Disease | None on record | — | — | — | — |
Ahn-Gook Pharmaceutical001540 · KOSDAQ | 2 assets: 2 Ph 3 | AG2304Phase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | ~$14M |
Akeso9926 · HKEX | 12 assets: 1 approved, 6 Ph 3, 5 Ph 2 | IvonescimabPhase 3 · Non-Small Cell Lung CancerReliable signal | Nov 2026Cadonilimab · Phase 3 | — | $1.0BDec 2024 | ~14.1 qtrs | $166M |
Aktis Oncology, Inc.AKTS · | 2 assets: 2 Ph 1 | AKY-1189Phase 1 · Non-Small Cell Lung Cancer | Dec 2027AKY-2519 · Phase 1 | — | $494MSep 2026 | ~23.0 qtrs | ~$94M |
Alar Pharmaceuticals6785 · TPEx | 1 asset: 1 Ph 1 | ALA-3000Phase 1 · Major Depressive DisorderPartial signal | None on record | — | — | — | — |
Alebund Pharmaceuticals9637 · HKEX | 1 asset: 1 Ph 3 | AP301 (fiber-iron phosphate binder)Phase 3 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | $52M |
Aligos TherapeuticsALGS · Nasdaq | 1 asset: 1 Ph 2 | ALG-055009Phase 2 · MASH / NASH | None on record | — | $32MSep 2026 | ~1.9 qtrs | $83M |
ALK-AbellóALK B · Nasdaq Copenhagen | 1 asset: 1 approved | Approved assets only | Apr 2027Epinephrine · Approved | — | — | — | — |
Alkem LaboratoriesALKEM · NSE | 1 asset: 1 Ph 3 | EvogliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Alkermes plcALKS · Nasdaq | 6 assets: 5 approved, 1 Ph 3 | AlixorextonPhase 3 · Narcolepsy | Nov 2026Alixorexton · Phase 2 | — | $755MSep 2026 | Cash-flow positive | $430M |
Allist Pharmaceuticals688578 · SSE STAR Market | 4 assets: 3 Ph 3, 1 Ph 1 | GlecirasibPhase 3 · Non-Small Cell Lung CancerWeak signal | Dec 2026AST2303 · Phase 1 | — | — | — | $75M |
AlmirallALM · BME | 5 assets: 3 approved, 1 Ph 3, 1 other | Almotriptan (Axert)US approval withdrawn · MigraineWeak signal | 25 Apr 2027lebrikizumab · Phase 3 | — | $405MJun 2026 | — | — |
Alpha Compute CorpALP · Nasdaq | 2 assets: 2 Ph 2 | TT-10Phase 1/2 · Non-Small Cell Lung Cancer | 1 Dec 2028TT-10 · Phase 1/2 | — | $0.2MSep 2025 | Ended Oct 2025 | ~$5.4M |
Alphamab Oncology9966 · HKEX | 4 assets: 2 Ph 3, 2 Ph 2 | Anbenitamab repodatecanPhase 3 · HR+/HER2- Metastatic Breast Cancer | 30 Dec 2026Anbenitamab repodatecan · Phase 3 | — | $193MDec 2025 | ~12.2 qtrs | ~$70M |
Alteogen Inc.196170 · KOSDAQ | 1 asset: 1 other | Aflibercept (Eyluxvi)Age-Related Macular Degeneration | None on record | — | — | — | — |
AlvotechALVO · Nasdaq | 4 assets: 2 approved, 2 other | Aflibercept (Afiveg)Age-Related Macular Degeneration | None on record | — | $172MDec 2025 | ~26.3 qtrswith a later raise | $184M |
AlzeCure PharmaALZCUR · Spotlight Stock Market | 1 asset: 1 Ph 1 | ACD856Phase 1 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Alzinova ABALZ · Nasdaq First North | 1 asset: 1 Ph 1 | ALZ-101Phase 1 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Amneal PharmaceuticalsAMRX · NYSE | 6 assets: 6 approved | Approved assets only | None on record | — | $180MSep 2026 | Cash-flow positive | $181M |
Amphastar Pharmaceuticals, Inc.AMPH · Nasdaq | 4 assets: 4 approved | Approved assets only | None on record | — | $231MSep 2026 | Cash-flow positive | $92M |
Anbogen Therapeutics, Inc.7784 · TPEx | 1 asset: 1 Ph 2 | GozanertinibPhase 1/2 · Non-Small Cell Lung Cancer | Nov 2026Gozanertinib · Phase 1/2 | — | — | — | — |
AnGes4563 · TSE | 1 asset: 1 Ph 3 | Beperminogene perplasmid (HGF plasmid)Phase 3 · Atherosclerotic Cardiovascular Disease | None on record | — | $12MDec 2025 | Ended Feb 2026 | $24M |
ANI Pharmaceuticals, Inc.ANIP · Nasdaq | 4 assets: 4 approved | Approved assets only | 18 Dec 2029Anastrozole · Phase 3 | — | $421MSep 2026 | Cash-flow positive | $51M |
Antengene Corporation Limited6996 · HKEX | 2 assets: 1 approved, 1 Ph 2 | OnatasertibPhase 2 · Non-Small Cell Lung CancerWeak signal | Dec 2026Selinexor · Phase 2/3 | — | $111MJun 2025 | ~21.0 qtrs | ~$22M |
Anterogen065660 · KOSDAQ | 1 asset: 1 Ph 2 | ALLO-ASCPhase 2 · Dystrophic Epidermolysis BullosaWeak signal | None on record | — | — | — | — |
AP Biosciences Inc.6945 · TPEx | 2 assets: 2 Ph 2 | B1962Phase 2 · Non-Small Cell Lung Cancer | Dec 2026AP203 · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 2 | MetacavirPhase 2 · Chronic Hepatitis B | None on record | — | — | — | — | |
AprilBio397030 · KOSDAQ | 1 asset: 1 Ph 2 | EVO301Phase 2 · Atopic DermatitisPartial signal | None on record | — | — | — | — |
Aptabio Therapeutics293780 · KOSDAQ | 1 asset: 1 Ph 2 | IsuzinaxibPhase 2 · Type 2 DiabetesPartial signal | 30 Jun 2027Isuzinaxib · Phase 2 | — | — | — | — |
Arctic BiosciencePrivate | 1 asset: 1 Ph 2 | HRO350Phase 2 · Psoriasis | None on record | — | — | — | — |
Arecor LimitedAREC · AIM | 1 asset: 1 Ph 1 | Insulin aspart (AT278)Phase 1 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
argenxARGX · Nasdaq | 2 assets: 2 approved | Approved assets only | None on record | — | $702MDec 2023 | — | — |
Artgen BiotechABIO · MOEX | 1 asset: 1 Ph 3 | NeovasculgenPhase 2/3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | — |
Asahi Kasei Corporation3407 · TSE | 2 assets: 1 approved, 1 Ph 2 | SetanaxibPhase 2 · Primary Biliary CholangitisPartial signal | Mar 2027Budesonide (targeted-release) · Approved | — | — | — | — |
Ascendis Pharma A/SASND · Nasdaq | 2 assets: 2 approved | Approved assets only | Aug 2027palopegteriparatide · Phase 3 | — | $724MDec 2025 | Cash-flow positive | $344M |
| 5 assets: 3 Ph 3, 1 Ph 2, 1 Ph 1 | LisaftoclaxPhase 3 · Acute Myeloid LeukemiaWeak signal | Dec 2026Lisaftoclax · Phase 2 | — | $122MDec 2024 | ~31.6 qtrs | $132M | |
Ascletis Pharma1672 · HKEX | 4 assets: 3 Ph 3, 1 Ph 1 | DenifanstatPhase 3 · Recurrent GlioblastomaReliable signal | Dec 2026Envafolimab · Phase 2 | — | $206MDec 2025 | ~4.1 qtrs | $57M |
Asieris Pharmaceuticals688176 · SSE STAR Market | 1 asset: 1 Ph 1 | NepicastatPhase 1 · Ulcerative ColitisWeak signal | None on record | — | $91MMar 2026 | ~5.6 qtrs | $49M |
Astellas Pharma4503 · TSE | 15 assets: 4 approved, 4 Ph 3, 4 Ph 2, 3 Ph 1 | RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal | 30 Dec 2026ASP546C · Phase 1/2 | — | $1.8BMar 2026 | — | $2.1B |
Aurinia PharmaceuticalsAUPH · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | aritinerceptPhase 1/2 · Generalized Myasthenia Gravis | 2 Mar 2029aritinercept · Phase 1/2 | — | $487MSep 2026 | Cash-flow positive | $48M |
BayerBAYN · Xetra | 21 assets: 12 approved, 3 Ph 3, 3 Ph 2, 1 Ph 1, 2 other | MiglitolUS approval withdrawn · Type 2 DiabetesPartial signal | Dec 2026Mosliciguat · Phase 2 | — | $6.6BMar 2026 | Ended Aug 2026 | ~$6.6B |
BeBetter Med688759 · SSE STAR Market | 4 assets: 2 Ph 3, 2 Ph 2 | IfupinostatPhase 3 · Relapsed/Refractory Diffuse Large B-Cell LymphomaWeak signal | Jun 2027BEBT-109 · Phase 2 | — | $144MDec 2025 | ~6.7 qtrs | $17M |
Beijing Biostar Pharmaceuticals2563 · HKEX | 1 asset: 1 Ph 3 | UtidelonePhase 3 · Non-Small Cell Lung CancerPartial signal | 1 Dec 2026Utidelone · Phase 2 | — | — | — | — |
Beijing InnoCare Pharma Tech Co.9969 · HKEX | 5 assets: 1 approved, 3 Ph 3, 1 Ph 2 | FadeucravacitinibPhase 3 · PsoriasisPartial signal | 25 Nov 2026Soficitinib (ICP-332) · Phase 3 | — | $1.1BMar 2026 | Profitable | ~$132M |
Betta Pharmaceuticals Co.300558 · SZSE ChiNext | 9 assets: 1 approved, 3 Ph 3, 3 Ph 2, 2 Ph 1 | BefotertinibPhase 3 · Non-Small Cell Lung CancerPartial signal | Dec 2026BPI-371153 · Phase 1 | — | — | Profitable | — |
BicycleTx LimitedBCYC · Nasdaq | 2 assets: 2 Ph 2 | Nuzefatide pevedotinPhase 2 · Pancreatic Ductal Adenocarcinoma | 31 Dec 2026Nuzefatide pevedotin · Phase 1/2 | — | $470MSep 2026 | ~10.7 qtrs | $175M |
Bio-Path Holdings, Inc.BPTH · OTC | 2 assets: 1 Ph 2, 1 Ph 1 | PrexigebersenPhase 2 · Acute Myeloid LeukemiaWeak signal | Mar 2027BP1002 · Phase 1 | —no price since 18 Aug 2026 | <$0.1MMar 2026 | Ended Apr 2026 | $8.1M |
Bio-Thera Solutions688177 · SSE STAR Market | 7 assets: 3 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1 | BAT3306Phase 3 · Non-Small Cell Lung CancerPartial signal | 31 Dec 2026Vedastotug · Phase 1/2 | — | — | — | — |
BioArctic ABBIOA B · Nasdaq Stockholm | 1 asset: 1 Ph 2 | exidavnemabPhase 2 · Parkinson's DiseaseWeak signal | None on record | — | — | — | — |
BioAtla, Inc.BCAB · OTC | 3 assets: 3 Ph 2 | Ozuriftamab vedotinPhase 2 · Head and Neck Squamous Cell CarcinomaPartial signal | None on record | —no price since 28 Aug 2026 | $1.5MJun 2026 | Ended Jul 2026 | $25M |
BioconBIOCON · NSE | 3 assets: 2 approved, 1 Ph 1 | ItolizumabPhase 1 · Psoriasis | None on record | — | $259MMar 2026 | — | $111M |
BioInvent International ABBINV · Nasdaq Stockholm | 1 asset: 1 Ph 2 | BI-1910Phase 1/2 · Non-Small Cell Lung Cancer | 14 Jul 2027BI-1910 · Phase 1/2 | —no price since 25 Sep 2026 | — | — | — |
BioXcel Therapeutics, Inc.BTAI · OTC | 1 asset: 1 Ph 3 | Dexmedetomidine (Igalmi)Phase 3 · SchizophreniaReliable signal | 31 Jul 2027Dexmedetomidine (Igalmi) · Phase 1 | —no price since 4 Sep 2026 | $14MJun 2026 | Ended Oct 2026 | $22M |
| 1 asset: 1 Ph 2 | SilevertinibPhase 1/2 · Non-Small Cell Lung Cancer | Mar 2028Silevertinib · Phase 1/2 | — | $103MSep 2026 | ~12.3 qtrs | $28M | |
Boryung Pharmaceutical003850 · KOSPI | 1 asset: 1 Ph 3 | Fimasartan/atorvastatin/ezetimibe (BR1017)Phase 3 · HypertensionPartial signal | None on record | — | $170MMar 2026 | — | $38M |
Bright Minds Biosciences Inc.DRUG · Nasdaq | 1 asset: 1 Ph 2 | BMB-101Phase 2 · Epilepsy | Nov 2026BMB-101 · Phase 2 | — | $4.2MSep 2024 | ~12.4 qtrs | $0.9M |
BrightGene Bio-Medical Technology688166 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | BGM0504Phase 3 · ObesityPartial signal | 28 Feb 2027BGM0504 · Phase 2 | — | — | — | $83M |
BrightPath Biotherapeutics Co., Ltd.4594 · TSE | 1 asset: 1 Ph 1 | BP2202Phase 1 · Multiple Myeloma | 31 Dec 2027BP2202 · Phase 1 | — | $14MMar 2026 | ~6.3 qtrs | — |
Brii Biosciences2137 · HKEX | 1 asset: 1 Ph 3 | Tobevibart (VIR-3434)Phase 3 · Chronic Hepatitis Delta | Dec 2026Tobevibart (VIR-3434) · Phase 3 | — | — | — | — |
Can-Fite BioPharmaCANF · Nasdaq | 2 assets: 2 Ph 3 | NamodenosonPhase 3 · Hepatocellular CarcinomaPartial signal | 31 Aug 2027Piclidenoson · Phase 2 | — | $8.5MDec 2025 | Ended Mar 2026 | $6.7M |
Cantargia ABCANTA · Nasdaq Stockholm | 1 asset: 1 Ph 2 | NadunolimabPhase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record | — | $24MMar 2026 | ~7.4 qtrs | — |
CARsgen Therapeutics Holdings Limited2171 · HKEX | 2 assets: 2 Ph 2 | Zevorcabtagene autoleucelPhase 1/2 · Multiple MyelomaWeak signal | 15 Jun 2027CT071 · Phase 1/2 | — | $203MDec 2024 | Ended Oct 2026 | $66M |
CASI Pharmaceuticals, Inc.CASIF · OTC | 2 assets: 1 approved, 1 Ph 2 | CID-103Phase 2 · Immune ThrombocytopeniaWeak signal | 30 Nov 2028CID-103 · Phase 2 | —no price since 18 Aug 2026 | $5.6MDec 2025 | Ended Apr 2026 | $6.3M |
Catalyst Pharmaceuticals, Inc.CPRX · Nasdaq | 1 asset: 1 approved | Approved assets only | 6 Apr 2027Perampanel · Phase 2 | —no price since 14 Jul 2026 | — | — | — |
Celltrion068270 · KOSPI | 11 assets: 8 approved, 3 Ph 3 | CT-P44Phase 3 · Multiple Myeloma | Feb 2027CT-P51 · Phase 3 | — | $679MDec 2024 | Profitable | — |
Celon PharmaCLN · GPW | 2 assets: 2 Ph 2 | CPL500036Phase 2 · Parkinson's DiseaseReliable signal | None on record | — | — | — | — |
CERo Therapeutics Holdings, Inc.CERO · OTC | 1 asset: 1 Ph 1 | CER-1236Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026CER-1236 · Phase 1 | —no price since 18 Aug 2026 | $0.7MSep 2026 | Ended Oct 2026 | $7.3M |
Chengdu Kanghong Pharmaceutical002773 · SZSE | 2 assets: 2 Ph 3 | KH607Phase 3 · Major Depressive DisorderPartial signal | Dec 2027KH607 · Phase 3 | — | — | — | $56M |
China Medical System867 · HKEX | 9 assets: 5 approved, 4 Ph 3 | DesidustatPhase 3 · Chronic Kidney DiseasePartial signal | 31 Jan 2027CMS-D001 · Phase 2 | — | — | — | $81M |
China Resources Double-Crane Pharmaceutical600062 · SSE | 1 asset: 1 Ph 3 | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
China Resources Sanjiu Medical & Pharmaceutical000999 · SZSE | 2 assets: 1 Ph 3, 1 other | BGM0504Phase 3 · ObesityPartial signal | 28 Feb 2027BGM0504 · Phase 2 | — | $666MDec 2025 | — | $241M |
Chipscreen Biosciences688321 · SSE | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | 18 Sep 2027CS32582 · Phase 1/2 | — | — | — | — |
Chong Kun Dang Pharmaceutical185750 · KOSPI | 9 assets: 1 approved, 3 Ph 3, 2 Ph 2, 3 Ph 1 | CKD-701Phase 3 · Age-Related Macular DegenerationReliable signal | Dec 2029CKD-703 · Phase 1/2 | — | — | — | — |
Chordia Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | RogocekibPhase 1/2 · Acute Myeloid Leukemia | Jun 2028Rogocekib · Phase 1/2 | — | $16MMay 2026 | — | ~$21M |
Chugai Pharma4519 · TSE | 14 assets: 10 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1 | enicepatidePhase 3 · ObesityReliable signal | 30 Nov 2026Atezolizumab · Phase 3 | — | — | — | $1.3B |
CiplaCIPLA · NSE | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | VildagliptinPhase 3 · Type 2 DiabetesPartial signal | Mar 2027Afrezza · Phase 2 | — | — | — | — |
CJ Bioscience, Inc.311690 · KOSDAQ | 1 asset: 1 Ph 2 | CJRB-101Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Connect BiopharmaCNTB · Nasdaq | 1 asset: 1 Ph 3 | RademikibartPhase 3 · Atopic DermatitisPartial signal | 31 Dec 2026Rademikibart · Phase 3 | — | $31MJun 2026 | ~2.1 qtrs | $54M |
Consun Pharmaceutical Group1681 · HKEX | 1 asset: 1 Ph 1 | SK-08Phase 1 · Chronic Kidney Disease | None on record | — | $176MDec 2025 | — | — |
Cosmo N.V.COPN · SIX | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
CSPC Pharmaceutical Group1093 · HKEX | 11 assets: 8 Ph 3, 2 Ph 2, 1 other | PrusogliptinPhase 3 · Type 2 DiabetesReliable signal | 30 Dec 2026Anbenitamab repodatecan · Phase 3 | — | $1.4BDec 2025 | — | $809M |
CStone Pharmaceuticals2616 · HKEX | 2 assets: 1 approved, 1 Ph 3 | SugemalimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 30 Jul 2027Pralsetinib · Approved | — | $131MDec 2025 | Ended Jul 2026 | $43M |
Curacle365270 · KOSDAQ | 2 assets: 2 Ph 2 | CU01-1001Phase 2 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — |
CytoDynCYDY · OTCQB | 1 asset: 1 Ph 3 | LeronlimabPhase 2/3 · HIVPartial signal | Jan 2028Leronlimab · Phase 2 | —no price since 18 Aug 2026 | $16MAug 2026 | ~3.3 qtrs | $7.2M |
D&D Pharmatech347850 · KOSDAQ | 1 asset: 1 Ph 2 | ZabopegdutidePhase 2 · ObesityPartial signal | None on record | — | — | — | — |
Daewoong Pharmaceutical069620 · KOSPI | 7 assets: 4 Ph 3, 2 Ph 1, 1 other | EnavogliflozinPhase 3 · Type 2 DiabetesReliable signal | Nov 2027Enavogliflozin · Phase 3 | — | — | — | $155M |
Daiichi Sankyo4568 · TSE | 21 assets: 10 approved, 6 Ph 3, 4 Ph 2, 1 Ph 1 | Denosumab (Xgeva)Phase 3 · Multiple MyelomaReliable signal | 17 Dec 2026bevacizumab-awwb · Phase 1 | — | $3.1BMar 2026 | — | $3.0B |
DexTech Medical ABDEX · Spotlight Stock Market | 1 asset: 1 Ph 2 | ODX (Osteodex)Phase 1/2 · Multiple Myeloma | None on record | — | $1.6MJun 2025 | ~12.9 qtrs | — |
Dizal Pharmaceuticals688192 · SSE STAR Market | 2 assets: 1 approved, 1 Ph 2 | DZD6008Phase 1/2 · Non-Small Cell Lung Cancer | Jun 2027DZD6008 · Phase 1/2 | — | $42MDec 2025 | Ended Feb 2026 | $119M |
Dong-A ST170900 · KOSPI | 9 assets: 1 approved, 2 Ph 3, 2 Ph 2, 3 Ph 1, 1 other | EvogliptinPhase 3 · Type 2 DiabetesReliable signal | Dec 2026DA-2811 · Phase 2 | — | — | — | — |
DualityBio Inc.9606 · HKEX | 5 assets: 2 Ph 3, 3 Ph 2 | Trastuzumab pamirtecanPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Aug 2027Trastuzumab pamirtecan · Phase 1/2 | — | — | — | — |
Edding Genor Group Holdings Limited6998 · HKEX | 1 asset: 1 Ph 2 | EDP167Phase 2 · Atherosclerotic Cardiovascular DiseaseWeak signal | Nov 2027EDP167 · Phase 2 | — | — | Ended Jun 2024Dec 2023 | — |
Eisai4523 · TSE | 18 assets: 10 approved, 4 Ph 3, 4 Ph 2 | SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 29 Nov 2026Rimegepant (Nurtec ODT) · Phase 3 | — | $1.5BMar 2026 | — | $1.0B |
Emmaus Life SciencesEMMA · OTCQB | 1 asset: 1 approved | Approved assets only | None on record | — | $2.8MJun 2026 | Cash-flow positive | $0.2M |
Enanta Pharmaceuticals, Inc.ENTA · Nasdaq | 2 assets: 2 Ph 2 | EDP-323Phase 2 · Respiratory Syncytial Virus InfectionPartial signal | Dec 2026zelicapavir · Phase 2 | — | $190MJun 2026 | ~18.8 qtrs | $93M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.